Xtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.68 and traded as high as $0.8099. Xtant Medical shares last traded at $0.7840, with a volume of 139,917 shares traded.

Analyst Ratings Changes

Separately, BTIG Research decreased their price objective on shares of Xtant Medical from $2.00 to $1.50 and set a “buy” rating for the company in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $1.50.

Xtant Medical Stock Up 1.6%

The company has a market capitalization of $109.76 million, a PE ratio of 78.48 and a beta of -0.08. The stock’s fifty day moving average is $0.73 and its two-hundred day moving average is $0.68. The company has a current ratio of 2.21, a quick ratio of 1.06 and a debt-to-equity ratio of 0.35.

Xtant Medical (NYSEAMERICAN:XTNT) last posted its quarterly earnings data on Monday, November 10th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. The business had revenue of $27.77 million during the quarter, compared to the consensus estimate of $32.70 million. Xtant Medical had a net margin of 1.32% and a return on equity of 3.77%.

Hedge Funds Weigh In On Xtant Medical

Institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC increased its position in Xtant Medical by 500.3% in the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after buying an additional 57,000,000 shares during the last quarter. AWM Investment Company Inc. purchased a new position in shares of Xtant Medical during the 2nd quarter valued at $4,875,000. Crescent Grove Advisors LLC grew its stake in shares of Xtant Medical by 94.3% during the 2nd quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock worth $304,000 after acquiring an additional 200,000 shares during the period. Vanguard Group Inc. increased its holdings in Xtant Medical by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after acquiring an additional 104,159 shares during the last quarter. Finally, Mink Brook Asset Management LLC raised its stake in Xtant Medical by 125.8% in the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after acquiring an additional 60,997 shares during the period. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.